Loading organizations...
§ Private Profile · New York City, NY, USA
Specialized investment arm providing venture capital and private equity funding for biotechnology and healthcare companies.
AI Life Sciences Investments LLC is a venture capital and private equity investment vehicle focused on the biotechnology and healthcare sectors, based in New York City. Operating as a specialized life sciences investment arm of the privately held industrial group Access Industries, the firm is backed by the multi-billion-dollar capital of its parent organization. The firm generates financial returns through equity investments, capital appreciation, and strategic exits such as initial public offerings or acquisitions within the global biopharmaceutical and medical research markets. Its investment strategy has historically targeted both United States-based and Israeli-based biotechnology firms, with a portfolio that includes recognizable industry names such as Compugen and Chiasma. While the exact founding year of this specific limited liability company remains undisclosed, its parent organization was established in 1986 by billionaire founder and chairman Len Blavatnik.
The firm maintains its headquarters in New York, New York.
Yes, the firm participated in a $200 million funding round for Treeline Biosciences, alongside other investors.
The firm maintains its headquarters in New York, New York.
Yes, the firm participated in a $200 million funding round for Treeline Biosciences, alongside other investors.
The firm's headquarters are situated in New York, New York, positioning it within a significant hub for both financial services and life sciences research. This geographic location may facilitate its engagement with emerging companies and established institutions in the sector.
A notable instance of AI Life Sciences Investments LLC's investment activity is its participation in a funding round for Treeline Biosciences. The firm was among several investors that contributed to a $200 million funding initiative for Treeline Biosciences. This investment demonstrates AI Life Sciences Investments LLC's commitment to providing capital to organizations developing new solutions in the life sciences field.
The firm's involvement in such funding rounds underscores its function in the broader venture ecosystem, particularly in fostering growth and innovation within the life sciences. By specializing in this sector, AI Life Sciences Investments LLC contributes to the advancement of scientific and medical technologies.
AI Life Sciences Investments LLC has 1 tracked investment across 1 company. The latest tracked deal is $115.0M Series D in ILiAD Biotechnologies in February 2026.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Feb 10, 2026 | ILiAD Biotechnologies | $115.0M Series D | RA Capital Management | BNP Paribas Asset Management, Janus Henderson Investors, BNP Capital |